Employers have a responsibility to support the food as medicine movement and help employees who are food insecure, said Jay Bhatt, managing director of Deloitte Services and managing director of the Center for Health Solutions and Health Equity Institute. He made these comments last week at the MedCity INVEST conference in Chicago.
Enjoy extra savings when you purchase your extreme early bird INVEST Digital Health 2023 ticket now. Priced at only $295. Join us at Pegasus Park in Dallas, TX for a riveting day of content and networking.
Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.
Carrum Health's $45 million funding round was led by OMERS Growth Equity and included participation from Revelation Partners, Tiger Global, Wildcat Venture Partners, Cross Creek and SpringRock Ventures. It brings the company's total financing to about $96 million.
A group of federal agencies recently released an updated set of guidelines to help healthcare organizations protect themselves from ransomware attacks and the data breaches that often follow. The guidance lays out best practices to prevent the six major ways that bad actors gain access to providers' systems, which include compromised credentials and phishing.
Global funding for digital health companies finally stabilized in Q1 of this year. The sector raised $3.4 billion — this marks the first time the digital health world didn't experience a quarter-over-quarter funding decline since Q4 of 2021. By holding steady, digital health startups defied the dwindling fundraising totals seen across the broader venture capital landscape, where funding dropped by 13% quarter-over-quarter.
In addition to reducing workload, NLP and ambient voice technology can also improve the quality of care that clinicians provide. By analyzing EHRs and other patient data, NLP algorithms can identify potential health risk factors and recommend preventative measures.
Marstacimab, a Pfizer drug for both hemophilia A and B, met the main goal of a Phase 3 study and the company now plans to discuss the data with regulators. The Pfizer drug could beat to the market a Novo Nordisk drug that addresses the same novel target.
No comments:
Post a Comment